OCULAR THERAPEUTIX, INC Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
OCULAR THERAPEUTIX, INC (OCUL) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2022-02-28
- OCULAR THERAPEUTIX, INC unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $0.00.
- OCULAR THERAPEUTIX, INC unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $0.00.
- OCULAR THERAPEUTIX, INC unrecognized tax benefits, income tax penalties and interest expense for fiscal 2019 was $0.00.
- OCULAR THERAPEUTIX, INC unrecognized tax benefits, income tax penalties and interest expense for fiscal 2018 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |